Compare AXT Inc (AXTI) vs Eli Lilly And Co (LLY) Price & Performance

AXTI is trading at $76.84, up 4.11% with strong bullish momentum following better-than-expected Q2 2026 earnings. The stock shows bullish technical signals with support at $72 and resistance at $77. Recent financials indicate a turnaround with Q2 EPS of $0.19 beating estimates and revenue growth driven by record indium phosphide demand for AI data centers.

The outlook appears positive with strong AI-driven demand and capacity expansion plans, though valuation metrics remain elevated with P/S of 30.53. Key risks include execution challenges in meeting demand and competitive pressures in the semiconductor substrate market. Analyst consensus is strongly bullish with 73% buy ratings and $72.50 price target.

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.